Manager TitleAgeSince
Chief Executive Officer 48 2025-04-10
Chief Executive Officer - 2022-11-04
Director of Finance/CFO - 2018-04-23
Director TitleAgeSince
Director/Board Member 58 2008-05-13
Director/Board Member 78 2014-02-02
Director/Board Member - 2021-06-23
Date Insider Type Main position Quantity % Market Cap.
12/17/22 Buy

Chief Executive Officer

18,480 0.2673%
10/24/22 Sell

Chief Financial Officer

21,230 0.3100%
10/24/22 Sell

Head of Human Resources

18,140 0.2649%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-0.14% - - 105M
+1.07%-4.73%-3.96%+11.63% 46.35B
+0.25%+5.61%+404.21%+606.87% 40.13B
-0.27%+2.67%+10.54%+65.01% 36.33B
+0.35%-1.16%+7.11%-8.85% 34.6B
+3.14%+1.02%+3.72%+34.86% 26.77B
+0.47%-2.29% - - 16.66B
-0.73%+11.80%+37.49%+145.18% 16.91B
+0.42%-4.46%+4.80%+8.67% 13.05B
-2.68%-2.49%-1.27%-32.60% 13.05B
Average +0.20%+1.02%+57.83%+103.85% 27.09B
Weighted average by Cap. +0.46%+0.77%+76.79%+132.15%
Logo ONCODESIGN
ONCODESIGN specializes in preclinical pharmacological evaluation services of new cancer therapies on behalf of the pharmaceutical and biotechnological companies. The group also provides research and development of drugs and biomarkers primarily for the treatment of cancer. The group's activity is organized around 3 business units: - Service: discovery, identification and selection of new therapeutic targets in oncology; - Biotech: development of a portfolio of therapeutic and diagnostic projects alone or through partnerships; - Artificial Intelligence: development of a platform for selecting new therapeutic targets in oncology. 60.3% of sales are abroad.
Employees
236
  1. Stock Market
  2. Stocks
  3. ALONC Stock